<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.1d1" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher">REMEDIUM</journal-id><journal-title-group><journal-title>REMEDIUM</journal-title></journal-title-group><issn publication-format="print">1561-5936</issn><issn publication-format="electronic">2658-3534</issn><publisher><publisher-name>Joint-Stock Company Chicot</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1050</article-id><article-id pub-id-type="doi">10.21518/1561-5936-2019-3-20-25</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Supplies of medicinal products manufactured in the EAEU countries to Russia</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Yutkina</surname><given-names>Irina</given-names></name><bio></bio><email>noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff id="aff-1">RNC Pharma Analytics Company</aff><pub-date date-type="epub" iso-8601-date="2019-12-03" publication-format="electronic"><day>03</day><month>12</month><year>2019</year></pub-date><issue>3</issue><fpage>20</fpage><lpage>25</lpage><history><pub-date date-type="received" iso-8601-date="2022-03-18"><day>18</day><month>03</month><year>2022</year></pub-date></history><permissions><copyright-statement>Copyright © 2019,</copyright-statement><copyright-year>2019</copyright-year></permissions><abstract>EAEU countries to Russia shows a rather positive picture over the past three years. The rouble volume of products imported into our country shows double-digit growth rates, while the growth rates of monetary volumes noticeably outpace physical indicators. Changes in the range of products supplied substantially contributed to this growth. On the one hand, the products range is replenished with products of the upper price segment; on the other hand, supplies of individual low-cost MPs are reduced.</abstract><kwd-group xml:lang="en"><kwd>MP (medicinal product)</kwd><kwd>EAEU</kwd><kwd>imports</kwd><kwd>supplies</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>ЛП</kwd><kwd>ЕАЭС</kwd><kwd>импорт</kwd><kwd>объем поставок</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>ИАС «Клифар-Госреестр». БАД Экоцистин.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Листок-вкладыш к БАД Экоцистин.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Ребров Б.А. Альм. клин. мед. 2017; 45 (8): 665-673.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Зайцев А.В. с соавт. Метод. рек. №57. М., 2017.</mixed-citation></ref></ref-list></back></article>
